With its cam­pus ex­pand­ing as gene ther­a­py booms, Alde­vron brings in a top ex­ec from a medtech gi­ant to steer the course

We now know where Kevin Ballinger was head­ed when he un­ex­pect­ed­ly hand­ed in his res­ig­na­tion ear­li­er this month as one of the top EVPs at medtech gi­ant Boston Sci­en­tif­ic, where he’s spent the last 25 years.

Ballinger is land­ing in Far­go, ND, where he’s now tak­ing the reins as the new CEO at Alde­vron, one of the world’s top man­u­fac­tur­ers of plas­mid DNA, mR­NA, CRISPR/Cas9, vec­tors and more, serv­ing the bur­geon­ing world of gene ther­a­py de­vel­op­ers around the world.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER